In our recent multi-center study, we found that non-Asians with hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) were more likely to present with decompensated and advanced disease compared with Asians ¹. However, non-Asians were more likely to undergo curative HCC treatment versus Asians. Among patients without cirrhosis, non-Asians had a poorer 5-year survival versus Asians (38% versus 54%). The letter from Dr Jia and colleagues raises some points that merit discussion ².

中文翻译：

---

HBV 相关肝细胞癌：呼吁改善监测和与护理的联系

在我们最近的多中心研究中，我们发现与亚洲人相比，患有乙型肝炎病毒 (HBV) 相关肝细胞癌 (HCC) 的非亚洲人更可能出现失代偿和晚期疾病¹。然而，与亚洲人相比，非亚洲人更有可能接受治愈性 HCC 治疗。在没有肝硬化的患者中，非亚洲人的 5 年生存率低于亚洲人（38% 对 54%）。贾博士及其同事的来信提出了一些值得讨论的要点²。